Evidence map›Paper›PMID 37358142›Full record

ArticleCancer cytopathology2023

Examining longitudinal markers of bladder cancer recurrence through a semiautonomous machine learning system for quantifying specimen atypia from urine cytology.

Joshua J Levy, Natt Chan, Jonathan D Marotti, Nathalie J Rodrigues, A Aziz O Ismail, Darcy A Kerr, Edward J Gutmann, Ryan E Glass, Caroline P Dodge, Arief A Suriawinata and 3 more

Abstract read
In one paragraph

Article in Cancer cytopathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Joshua J LevyEmerging Diagnostic and Investigative Technologies, Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA.ORCID 0000-0001-8050-1291
Natt ChanProgram in Quantitative Biomedical Sciences, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire, USA.
Jonathan D MarottiEmerging Diagnostic and Investigative Technologies, Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA.ORCID 0000-0002-2181-3698
Nathalie J RodriguesEmerging Diagnostic and Investigative Technologies, Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA.
A Aziz O IsmailEmerging Diagnostic and Investigative Technologies, Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Darcy A KerrEmerging Diagnostic and Investigative Technologies, Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA.ORCID 0000-0002-3228-2044
Edward J GutmannEmerging Diagnostic and Investigative Technologies, Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA.ORCID 0000-0002-3392-4731
Ryan E GlassUPMC East, Pittsburg, Pennsylvania, USA.ORCID 0000-0002-8802-7288
Caroline P DodgeCambridge Health Alliance, Cambridge, Massachusetts, USA.
Arief A SuriawinataEmerging Diagnostic and Investigative Technologies, Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Brock C ChristensenDepartment of Epidemiology, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire, USA.
Xiaoying LiuEmerging Diagnostic and Investigative Technologies, Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Louis J VaickusEmerging Diagnostic and Investigative Technologies, Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA.

Funding

Zhao - Proj 2P20GM130454 · NIGMS · DARTMOUTH COLLEGE · PI MICHAEL L WHITFIELD · 2019 to 2026
$27.2M
Relation Between In-utero Vitamin D and Immune Function in Early Childhood P20GM104416 · NIGMS · DARTMOUTH COLLEGE · PI KARAGAS, MARGARET RITA · 2013 to 2022
$23.7M
Semi-automated bladder cancer screening using machine learning: clinical validation and implementation.K08CA267096 · NCI · DARTMOUTH-HITCHCOCK CLINIC · PI VAICKUS, LOUIS JOSEPH · 2022 to 2025
$949k
NCI NIH HHS K08 CA267096NIGMS NIH HHS P20 GM104416NIGMS NIH HHS P20 GM130454NIH HHS K08CA267096NIH HHS P20GM104416NIH HHS P20GM130454
6 · The paper itself

Abstract

backgroundUrine cytology is generally considered the primary approach for screening for recurrence of bladder cancer. However, it is currently unclear how best to use cytological examinations for assessment and early detection of recurrence, beyond identifying a positive finding that requires more invasive methods to confirm recurrence and decide on therapeutic options. Because screening programs are frequent, and can be burdensome, finding quantitative means to reduce this burden for patients, cytopathologists, and urologists is an important endeavor and can improve both the efficiency and reliability of findings. Additionally, identifying ways to risk-stratify patients is crucial for improving quality of life while reducing the risk of future recurrence or progression of the cancer.

methodsIn this study, a computational machine learning tool, AutoParis-X, was leveraged to extract imaging features from urine cytology examinations longitudinally to study the predictive potential of urine cytology for assessing recurrence risk. This study examined how the significance of imaging predictors changes over time before and after surgery to determine which predictors and time periods are most relevant for assessing recurrence risk.

resultsResults indicate that imaging predictors extracted using AutoParis-X can predict recurrence as well or better than traditional cytological/histological assessments alone and that the predictiveness of these features is variable across time, with key differences in overall specimen atypia identified immediately before tumor recurrence.

conclusionsFurther research will clarify how computational methods can be effectively used in high-volume screening programs to improve recurrence detection and complement traditional modes of assessment.

Indexed as

Urinary Bladder NeoplasmsHumansMachine LearningNeoplasm Recurrence, LocalQuality of LifeReproducibility of ResultsUrineartificial intelligencebladder cancerdeep learninglongitudinalmachine learningrecurrenceThe Paris Systemurine cytology

Identifiers

PMID37358142
PMCPMC10527805

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.